This is a preview of updates coming to the Technical Bulletin's website in April 2026. Return to current site.
Read more about the modernization release schedule in this announcement.
Comment via the yellow feedback button in the lower right hand corner of the page. Contact the NLM Help Desk with any questions or concerns.
This is archived content.
Links may have become inactive over time. Visit Archive-It to find the original published layout.
RxNorm December 2017 Release
RxNorm December 2017 Release. NLM Tech Bull. 2017 Nov-Dec;(419):b8.
December 04, 2017 [posted]
The RxNorm December 2017 full monthly release is available as of Monday, December 4, 2017. The United States Food and Drug Administration (FDA) started adding 4-letter suffixes to the nonproprietary ingredient name of new biological products. The FDA-designated distinguishing suffix is devoid of meaning and composed of four lowercase letters.
RxNorm is representing the nonproprietary ingredient name lacking the 4-letter suffix as an ingredient (TTY=IN). The more granular ingredient name with the 4-letter suffix is represented as a precise ingredient (TTY=PIN).
To illustrate, here are several RxNorm forms for the biological product Renflexis:
| TTY | RXCUI | String |
| SBD | 1927290 | infliximab-abda 100 MG Injection [Renflexis] |
| SCD | 1927285 | infliximab-abda 100 MG Injection |
| PIN | 1927283 | infliximab-abda |
| IN | 191831 | infliximab |
For more information, see Nonproprietary Naming of Biological Products: Guidance for Industry (PDF format) from the FDA.